M.D.C. Holdings, Inc. (NYSE:MDC) Expected to Post Earnings of $0.87 Per Share

Equities analysts expect that M.D.C. Holdings, Inc. (NYSE:MDC) will report earnings per share (EPS) of $0.87 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for M.D.C.’s earnings, with the lowest EPS estimate coming in at $0.82 and the highest estimate coming in at $0.95. M.D.C. reported earnings per share of $0.86 during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.2%. The company is scheduled to report its next quarterly earnings report after the market closes on Wednesday, October 30th.

According to Zacks, analysts expect that M.D.C. will report full year earnings of $3.67 per share for the current fiscal year, with EPS estimates ranging from $3.51 to $3.91. For the next year, analysts expect that the business will post earnings of $4.20 per share, with EPS estimates ranging from $3.90 to $4.35. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for M.D.C..

M.D.C. (NYSE:MDC) last announced its quarterly earnings results on Wednesday, July 31st. The construction company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.78 by $0.08. The firm had revenue of $732.84 million for the quarter, compared to analyst estimates of $727.20 million. M.D.C. had a return on equity of 13.24% and a net margin of 6.64%. The business’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.03 earnings per share.

Several equities analysts have recently commented on MDC shares. Raymond James upgraded M.D.C. from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $42.00 to $49.00 in a research note on Friday, September 13th. ValuEngine lowered M.D.C. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded M.D.C. from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a research note on Wednesday, July 10th. Wedbush lifted their target price on M.D.C. from $35.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, September 13th. Finally, JPMorgan Chase & Co. upgraded M.D.C. from an “underweight” rating to a “neutral” rating in a research note on Monday, July 8th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.75.

In other news, Director Paris G. Reece III sold 25,030 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $36.55, for a total transaction of $914,846.50. Following the sale, the director now owns 4,697 shares in the company, valued at $171,675.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael A. Berman sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $70.52, for a total value of $705,200.00. Following the sale, the director now owns 148,218 shares in the company, valued at approximately $10,452,333.36. The disclosure for this sale can be found here. Insiders sold 123,862 shares of company stock worth $5,162,869 in the last quarter. 26.30% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. Stephens Inc. AR purchased a new stake in shares of M.D.C. during the third quarter worth about $275,000. Smith Graham & Co. Investment Advisors LP grew its stake in shares of M.D.C. by 0.6% during the third quarter. Smith Graham & Co. Investment Advisors LP now owns 312,015 shares of the construction company’s stock worth $13,448,000 after acquiring an additional 1,770 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of M.D.C. during the third quarter worth about $203,000. Envestnet Asset Management Inc. grew its stake in shares of M.D.C. by 28.7% during the third quarter. Envestnet Asset Management Inc. now owns 13,180 shares of the construction company’s stock worth $568,000 after acquiring an additional 2,941 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of M.D.C. during the third quarter worth about $271,000. Institutional investors and hedge funds own 75.04% of the company’s stock.

Shares of M.D.C. stock traded down $0.16 during trading on Monday, hitting $45.84. 565,304 shares of the stock traded hands, compared to its average volume of 434,087. The firm has a market cap of $2.89 billion, a P/E ratio of 12.49, a price-to-earnings-growth ratio of 1.25 and a beta of 1.05. The company has a current ratio of 9.12, a quick ratio of 2.19 and a debt-to-equity ratio of 0.66. M.D.C. has a 52-week low of $25.14 and a 52-week high of $46.84. The stock’s fifty day simple moving average is $42.39 and its 200 day simple moving average is $35.91.

M.D.C. Company Profile

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

Featured Story: What is the balance sheet?

Get a free copy of the Zacks research report on M.D.C. (MDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.